Urinary -acetyl-beta-d-glucosaminidase (NAG) with Neutrophil Gelatinase-associated Lipocalin (NGAL) Improves the Diagnostic Value for Proximal Tubule Damage in Diabetic Kidney Disease

Overview

Journal 3 Biotech

Publisher Springer

Specialty Biotechnology

Date 2019 Feb 8

PMID 30729090

Citations 11

Authors

Khalid Siddiqui

Basim Al-Malki

Teena Puthiyaparampil George

Shaik Sarfaraz Nawaz

Khalid Al Rubeaan

Affiliations

Soon will be listed here.

Abstract

Screening for diabetic kidney disease (DKD) remains a challenge; however, there has been an ongoing research to investigate the diagnostic value of different biomarkers to identify DKD. The aim of this study was to assess the diagnostic value of both -acetyl-beta-d-glucosaminidase (NAG) and neutrophil gelatinase-associated lipocalin (NGAL) in the progression of DKD. This cross-sectional case-control study included 92 type 2 diabetic patients with or without DKD. Urinary NAG and NGAL were measured to evaluate their diagnostic values as biochemical markers related to DKD. Both urinary NAG and NGAL levels were significantly higher among patients with DKD. In multiple linear regression analysis, NAG showed a positive significant association with NGAL in the three different adjusted models, while no significant correlation with fasting blood glucose, glycated hemoglobin, serum creatinine, estimated glomerular filtration rate, and albumin creatinine ratio were observed. The area under the curve for NGAL was 0.659 ( = 0.01) and 0.564 ( = 0.297) for NAG in DKD patients. This study demonstrates the association between urinary NAG and NGAL as a tubular damage marker for DKD although longitudinal studies are needed to evaluate its diagnostic value.

Citing Articles

Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions.

Jha R, Lopez-Trevino S, Kankanamalage H, Jha J Biomedicines. 2024; 12(5).

PMID: 38791060 PMC: 11118045. DOI: 10.3390/biomedicines12051098.

Diagnostic value of α1-MG and URBP in early diabetic renal impairment.

Zhou Y, Zhang Y, Chen J, Wang T, Li H, Wu F Front Physiol. 2023; 14:1173982.

PMID: 37929213 PMC: 10621041. DOI: 10.3389/fphys.2023.1173982.

Evaluation of N-acetyl-β-D-glucosaminidase as a prognostic marker for diabetic nephropathy in type 2 diabetics: systematic review and meta-analysis.

Dos Santos Bitencourt A, Vargas Filho R, Prestes G, Uggioni M, Marcal F, Colonetti T Int Urol Nephrol. 2023; 56(5):1651-1661.

PMID: 37898960 DOI: 10.1007/s11255-023-03843-3.

Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status.

Liu X, Gong S, Ning Y, Li Y, Zhou H, He L BMC Nephrol. 2023; 24(1):208.

PMID: 37452282 PMC: 10347709. DOI: 10.1186/s12882-023-03262-7.

Sickle cell nephropathy: A review of novel biomarkers and their potential roles in early detection of renal involvement.

Safdar O, Baghdadi R, Alahmadi S, Fakieh B, Algaydi A World J Clin Pediatr. 2022; 11(1):14-26.

PMID: 35096543 PMC: 8771312. DOI: 10.5409/wjcp.v11.i1.14.

References

Bouvet B, Paparella C, Arriaga S, Monje A, Amarilla A, Almara A . Evaluation of urinary N-acetyl-beta-D-glucosaminidase as a marker of early renal damage in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2014; 58(8):798-801. DOI: 10.1590/0004-2730000003010. View

Mohammadi-Karakani A, Asgharzadeh-Haghighi S, Ghazi-Khansari M, Hosseini R . Determination of urinary enzymes as a marker of early renal damage in diabetic patients. J Clin Lab Anal. 2007; 21(6):413-7. PMC: 6649252. DOI: 10.1002/jcla.20212. View

Asare-Anane H, Twum F, Ofori E, Torgbor E, Amanquah S, Osafo C . Urinary Lysosomal Enzyme Activities and Albuminuria in Ghanaian Patients with Type 2 Diabetes Mellitus. Dis Markers. 2016; 2016:2810639. PMC: 4993916. DOI: 10.1155/2016/2810639. View

Ambade V, Sing P, Somani B, Basanna D . Urinary N-acetyl beta glucosaminidase and gamma glutamyl transferase as early markers of diabetic nephropathy. Indian J Clin Biochem. 2012; 21(2):142-8. PMC: 3454003. DOI: 10.1007/BF02912930. View

Dharmashankar K, Widlansky M . Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep. 2010; 12(6):448-55. PMC: 2982873. DOI: 10.1007/s11906-010-0150-2. View

Al-Rubeaan K, Siddiqui K, Alghonaim M, Youssef A, Alnaqeb D . The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters. Ann Saudi Med. 2018; 38(1):46-56. PMC: 6074186. DOI: 10.5144/0256-4947.2018.03.01.1010. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Al-Rubeaan K, Siddiqui K, Al-Ghonaim M, Youssef A, Al-Sharqawi A, Alnaqeb D . Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients. Sci Rep. 2017; 7(1):2684. PMC: 5457399. DOI: 10.1038/s41598-017-02421-9. View

Piwowar A, Knapik-Kordecka M, Fus I, Warwas M . Urinary activities of cathepsin B, N-acetyl-beta-D-glucosaminidase, and albuminuria in patients with type 2 diabetes mellitus. Med Sci Monit. 2006; 12(5):CR210-4. View

10.

Sheira G, Noreldin N, Tamer A, Saad M . Urinary biomarker N-acetyl-β-D-glucosaminidase can predict severity of renal damage in diabetic nephropathy. J Diabetes Metab Disord. 2015; 14:4. PMC: 4340101. DOI: 10.1186/s40200-015-0133-6. View

11.

. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View

12.

Liangos O, Perianayagam M, Vaidya V, Han W, Wald R, Tighiouart H . Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007; 18(3):904-12. DOI: 10.1681/ASN.2006030221. View

13.

Skalova S . The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Medica (Hradec Kralove). 2005; 48(2):75-80. View

14.

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

15.

Ketteler M, Block G, Evenepoel P, Fukagawa M, Herzog C, McCann L . Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med. 2018; 168(6):422-430. DOI: 10.7326/M17-2640. View

16.

Fu W, Xiong S, Fang Y, Wen S, Chen M, Deng R . Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine. 2011; 41(1):82-8. DOI: 10.1007/s12020-011-9509-7. View

17.

Assal H, Tawfeek S, Rasheed E, El-Lebedy D, Thabet E . Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes. 2013; 6:7-13. PMC: 3738377. DOI: 10.4137/CMED.S12633. View

18.

Hozo S, Djulbegovic B, Hozo I . Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13. PMC: 1097734. DOI: 10.1186/1471-2288-5-13. View

19.

Tramonti G, Kanwar Y . Tubular biomarkers to assess progression of diabetic nephropathy. Kidney Int. 2011; 79(10):1042-4. DOI: 10.1038/ki.2011.9. View

20.

Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J . Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol. 2006; 21(6):856-63. DOI: 10.1007/s00467-006-0055-0. View